Based on a symposium held in Boston, Aug. 1985. Twenty-one studies present the theory and handling of radioligand binding that has revolutionized the study of receptor function and compound discovery. they cover basic principles of receptor theory and data analysis, molecular modeling, and structure
Michael Williams COMMENTARIES EDITOR, BIOCHEMICAL PHARMACOLOGY & ADJUNCT PROFESSOR, DEPARTMENT OF MOLECULAR PHARMACOLOGY AND BIOLOGICAL CHEMISTRY, FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO. Mike retired from the pharmaceutical industry in 2010 after 34 years in drug discovery research with Merck, CIBA-Geigy, Abbott and Cephalon. He has been actively involved with the biotech industry as a consultant, SAB member and executive (Nova, Genset, Adenosine Therapeutics, Antalium, Tagacept, Elan, Molecumetics) and has published extensively in the areas of pharmacology and drug discovery. He received his PhD and DSc degrees from the University of London in an era long before e-books could be downloaded.